This page uses content from Wikipedia and is licensed under CC BY-SA.

Dianicline

Dianicline
Dianicline structure.svg
Dianicline-3D-balls.png
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC13H16N2O
Molar mass216.278 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Dianicline (SSR-591,813) is a drug developed by Sanofi-Aventis which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It is being developed as a medication for the treatment of nicotine dependence to assist in smoking cessation.[1] Dianicline is very similar to the already marketed drug varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials.[2][3][4]

References

  1. ^ Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, et al. (July 2003). "SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation". The Journal of Pharmacology and Experimental Therapeutics. 306 (1): 407–20. doi:10.1124/jpet.103.049262. PMID 12682217.
  2. ^ Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs. 2006; 15(2):107-116.
  3. ^ Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation
  4. ^ "Sanofi Pipeline" (PDF). Archived from the original (PDF) on 2008-12-04. Retrieved 2009-06-24.